Evidence map›Paper›PMID 38058257›Full record

ArticleNeuropsychopharmacology reports2024

Quantification of cytosine modifications in the aged mouse brain.

Hiroko Sugawara, Akitoshi Date, Satoshi Fuke, Yutaka Nakachi, Tadafumi Kato, Minoru Narita, Miki Bundo, Kazuya Iwamoto

Open access · goldAbstract read
In one paragraph

Article in Neuropsychopharmacology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Hiroko SugawaraDepartment of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-5479-6161
Akitoshi DateDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
Satoshi FukeLab for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Wako, Japan.
Yutaka NakachiDepartment of Molecular Brain Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Tadafumi KatoLab for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Wako, Japan.ORCID https://orcid.org/0000-0001-7856-3952
Minoru NaritaDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan.
Miki BundoLab for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Wako, Japan.
Kazuya IwamotoLab for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Wako, Japan.ORCID https://orcid.org/0000-0002-1780-692X
RIKEN Center for Brain Science · JPHoshi University · JPKumamoto University · JPMitsubishi Chemical (Japan) · JPOsaka University of Economics · JP

Funding

Japan Agency for Medical Research and Development JP19dm0207074JSPS KAKENHI 18H05428JSPS KAKENHI 18H05430JSPS KAKENHI 18K15486JSPS KAKENHI 21K07548
6 · The paper itself

Abstract

Quantifying cytosine modifications in various brain regions provides important insights into the gene expression regulation and pathophysiology of neuropsychiatric disorders. In this study, we quantified 5-methylcytosine (5-mC), 5-hydroxymethylation (5-hmC), and 5-formylcytosine (5-fC) levels in five brain regions (the frontal lobe, cerebral cortical region without frontal lobe, hippocampus, basal ganglia, and the cerebellum) and the heart at three developmental periods (12, 48, and 101 weeks). We observed significant regional variations in cytosine modification. Notably, regional variations were generally maintained throughout development, suggesting that epigenetic regulation is unique to each brain region and remains relatively stable with age. The 5-mC and 5-hmC levels were positively correlated, although the extent of the correlations seemed to differ in different brain regions. On the contrary, 5-fC levels did not correlate with 5-mC or 5-hmC levels. Additionally, we observed an age-dependent decrease in 5-fC levels in the basal ganglia, suggesting a unique epigenetic regulation mechanism. Further high-resolution studies using animal models of neuropsychiatric disorders as well as postmortem brain evaluation are warranted.

Indexed as

CytosineEpigenesis, Genetic5-MethylcytosineAnimalsBrainCerebellumMice5-MethylcytosineCytosine5-formylcytosine: 5-fC5-hydroxymethycytosine: 5-hmC5-methylcytosine: 5-mCagingbasal ganglia

Identifiers

PMID38058257
PMCPMC10932792
OpenAlexW4389452494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.